【摘要】 目的 探讨甘精胰岛素联合格列美脲及诺和锐30对HbA1c>9%的初诊T2DM患者血糖波动的影响。 方法 将46例新诊断的T2DM患者随机分为甘精胰岛素联合格列美脲组与诺和锐30组。甘精胰岛素联合格列美脲组予以睡前皮下注射甘精胰岛素联合口服格列美脲治疗12周;诺和锐30组予以诺和锐30于早晚餐时皮下注射12周，对比两组治疗前后血糖谱的变化。 结果 甘精胰岛素联合格列美脲组与诺和锐30组血糖均得到效控制，但甘精胰岛素联合格列美脲组血糖波动小、低血糖事件发生率低、胰岛素用量少(P<0.05)。 结论 甘精胰岛素联合格列美脲对HbA1c>9%的初诊T2DM患者是一种更为安全、方便的治疗方案。 【关键词】 甘精胰岛素;格列美脲;血糖波动;动态血糖监测

　　Effect of glargine combined with glimepride on blood glucose variability in newly diagnosed type 2 diabetic patients.YU Wei-wei, LI Cai-ping.  Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

　　Corresponding author: Li Cai-ping, E-mail: yuweiwei75@gmail.com

　　【Abstract】 Objective To explore the effect of glargine combined with glimepride on blood glucose variability in newly diagnosed type 2 diabetic patients with HbA1c>9%. Methods Forty-six patients were randomized into two groups and treated with glargine and glimepiride or insulin aspart 30 respectively for 12 weeks. The daily blood glucose level was measured and compared with the continuous glucose monitoring system before and after intensive therapy in each group. Results The blood glucose levels in both groups were well controlled. However, there was a more stable blood glucose profile, less hypoglycemia, and smaller insulin dosage in the group treated with glargine + glimepiride (P<0.05). Conclusion Glimepiride combined with glargine is more convenient, and safe as well, than insulin aspart 30 in the treatment for newly diagnosed type 2 diabetic patients with HbA1c>9%.

　　【key words】 Glargine; Glimepride; Blood glucose variability; Continuous glucose monitoring